Cargando…

I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma

Background: Multiple myeloma (MM) is an incurable hematologic cancer, accompanied by excessive osteoclast formation and inflammatory cytokine secretion. The mechanisms by which bromodomain and extra-terminal domain (BET) protein inhibitor I-BET151 regulates osteoclast differentiation and inflammator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Ning-Hong, Zheng, Ji-Fu, Zi, Fu-Ming, Cheng, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522735/ https://www.ncbi.nlm.nih.gov/pubmed/30455393 http://dx.doi.org/10.1042/BSR20181245

Ejemplares similares

Bromodomain inhibitor I‐BET151 suppresses immune responses during fungal–immune interaction
por: Domínguez‐Andrés, Jorge, et al.
Publicado: (2019)

Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells
por: Kang, Sun Kyoung, et al.
Publicado: (2020)

Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
por: Yao, Zhicheng, et al.
Publicado: (2022)

Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
por: Lai, Jiacheng, et al.
Publicado: (2021)

BET Bromodomain Inhibitor iBET151 Impedes Human ILC2 Activation and Prevents Experimental Allergic Lung Inflammation
por: Kerscher, Bernhard, et al.
Publicado: (2019)

The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats
por: Piquereau, Jérôme, et al.
Publicado: (2019)

BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
por: Roberts, Thomas C., et al.
Publicado: (2017)

Bi-directional regulation of cartilage metabolism by inhibiting BET proteins—analysis of the effect of I-BET151 on human chondrocytes and murine joints
por: Dai, Jin, et al.
Publicado: (2018)

BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell
por: Deeney, Jude T., et al.
Publicado: (2016)

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
por: Cribbs, Adam P., et al.
Publicado: (2021)

BRD4: A BET(ter) target for the treatment of AML?
por: Valent, Peter, et al.
Publicado: (2014)

BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice
por: Korb, Erica, et al.
Publicado: (2015)

Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB
por: Gao, Si-yong, et al.
Publicado: (2017)

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
por: Coudé, Marie-Magdelaine, et al.
Publicado: (2015)

BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4
por: Ahmed, Nasiha S., et al.
Publicado: (2021)

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
por: Zengerle, Michael, et al.
Publicado: (2015)

Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
por: Wang, Wenyu, et al.
Publicado: (2021)

Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts
por: Zupan, Janja, et al.
Publicado: (2013)

The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice
por: Benito, E, et al.
Publicado: (2017)

Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4
por: Calder, Jack, et al.
Publicado: (2021)

Phosphorylation-dependent BRD4 dimerization and implications for therapeutic inhibition of BET family proteins
por: Malvezzi, Francesca, et al.
Publicado: (2021)

BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity
por: Khoueiry, P., et al.
Publicado: (2019)

Serpinb1a suppresses osteoclast formation
por: Ishida, Masayoshi, et al.
Publicado: (2021)

Zebrafish brd2a and brd2b are paralogous members of the bromodomain-ET (BET) family of transcriptional coregulators that show structural and expression divergence
por: DiBenedetto, Angela J, et al.
Publicado: (2008)

Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
por: Bolden, Jessica E., et al.
Publicado: (2014)

The BET Family Member BRD4 Interacts with OCT4 and Regulates Pluripotency Gene Expression
por: Wu, Tao, et al.
Publicado: (2015)

Blocking the ZZ Domain of Sequestosome1/p62 Suppresses Myeloma Growth and Osteoclast Formation In Vitro and Induces Dramatic Bone Formation in Myeloma-Bearing Bones In Vivo
por: Teramachi, Jumpei, et al.
Publicado: (2015)

The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
por: Jia, Si-Qi, et al.
Publicado: (2022)

Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption
por: Kitaura, Hideki, et al.
Publicado: (2020)

The Function of Naringin in Inducing Secretion of Osteoprotegerin and Inhibiting Formation of Osteoclasts
por: Xu, Tong, et al.
Publicado: (2016)

BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion
por: Blee, Alexandra M., et al.
Publicado: (2016)

BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer
por: Hajmirza, Azadeh, et al.
Publicado: (2018)

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
por: Dai, Xiangpeng, et al.
Publicado: (2017)

Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer
por: Ding, Donglin, et al.
Publicado: (2022)

MicroRNA-151a-3p Functions in the Regulation of Osteoclast Differentiation: Significance to Postmenopausal Osteoporosis
por: He, Yuehui, et al.
Publicado: (2021)

Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma
por: Mansour, Anna, et al.
Publicado: (2017)

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
por: Weisberg, Ellen, et al.
Publicado: (2022)

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

IL-27 Modulates the Cytokine Secretion in the T Cell–Osteoclast Crosstalk During HIV Infection
por: Li, Tong, et al.
Publicado: (2022)

Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma
por: Tiago, Manoela, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6qhfubt73kh5tesjbvklgfa0g2